Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 22Leukemia, Myeloid, Acute 21Lymphoma, Non-Hodgkin 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 9Hodgkin Disease 8Myelodysplastic Syndromes 7Neoplasms, Plasma Cell 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia 6Recurrence 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Gliosarcoma 3Glioblastoma 3Sezary Syndrome 2Myeloproliferative Disorders 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Glioma 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Sarcoma, Myeloid 1

Interventions

Temozolomide 61Radiotherapy 25Bevacizumab 21Magnetic Resonance Spectroscopy 20Irinotecan 18Filgrastim 15Carboplatin 15Carmustine 11Surgical Procedures, Operative 10Etoposide 9antineoplaston AS 2-1 8antineoplaston A10 8Specimen Handling 8sargramostim 7Radiation 7Peripheral Blood Stem Cell Transplantation 7Everolimus 7Biopsy 7Vincristine 6Radiotherapy, Intensity-Modulated 6Procarbazine 6O(6)-benzylguanine 6Erlotinib Hydrochloride 6Topotecan 5Melphalan 5Magnetic Resonance Imaging 5Lomustine 5Genetic Therapy 5Cyclophosphamide 5Aminolevulinic Acid 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Astrocytoma × plerixafor × Clear all
NCT01339039 2017-11-17

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Dana-Farber Cancer Institute

Phase 1 Terminated
26 enrolled
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡